| Literature DB >> 33179788 |
Saber Soltani1,2, Milad Zandi1,2, Parisa Shiri Aghbash3, Masoud Rezaei4, Nader Mohammadzadeh5, Alireza Afsharifar6, Vahdat Poortahmasebi3.
Abstract
The necessity and impact of SARS-CoV2 on the world's health have led to developing and producing practical and useful vaccines for this deadly respiratory virus. Since April 2020, a vaccine for the virus has been developed. Given that comorbidities such as diabetes, hypertension, and cardiovascular disease are more prone to viruses and the risk of infection, vaccines should be designed to protect against high-risk respiratory illnesses. Including SARS, MERS, influenza, and the SARS-CoV-2 provide a safe immune response. Here, we review the information and studies that have been done to help develop strategies and perspectives for producing a safe and ideal vaccine to prevent COVID-19 in normal people, especially at high-risk groups such as diabetes patients.Entities:
Keywords: COVID-19; Diabetes; SARS-CoV-2; Vaccine
Mesh:
Substances:
Year: 2021 PMID: 33179788 DOI: 10.1002/bab.2076
Source DB: PubMed Journal: Biotechnol Appl Biochem ISSN: 0885-4513 Impact factor: 2.431